Leonora E. Long

ORCID: 0000-0002-1759-4138
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cannabis and Cannabinoid Research
  • Neurotransmitter Receptor Influence on Behavior
  • Neuroscience and Neuropharmacology Research
  • Pancreatic function and diabetes
  • Neurogenesis and neuroplasticity mechanisms
  • Neuroscience of respiration and sleep
  • Diet, Metabolism, and Disease
  • Genetics and Neurodevelopmental Disorders
  • Health Literacy and Information Accessibility
  • Electron Spin Resonance Studies
  • Ginkgo biloba and Cashew Applications
  • Ion Channels and Receptors
  • Mobile Health and mHealth Applications
  • Advanced NMR Techniques and Applications
  • Telemedicine and Telehealth Implementation
  • Diversity and Career in Medicine
  • Lanthanide and Transition Metal Complexes
  • Facial Nerve Paralysis Treatment and Research
  • Lysosomal Storage Disorders Research
  • Advanced Glycation End Products research
  • Health and Medical Research Impacts
  • Ear Surgery and Otitis Media
  • Sleep and Wakefulness Research
  • Biochemical Analysis and Sensing Techniques
  • Cardiovascular Health and Disease Prevention

UNSW Sydney
2011-2024

St George Hospital
2024

Sutherland Hospital
2024

The University of Sydney
2007-2019

Schizophrenia Research Institute
2009-2018

Neuroscience Research Australia
2009-2018

Garvan Institute of Medical Research
2009

Pharmaceutical Biotechnology (Czechia)
2005-2006

Monash University
2004-2005

The schizophrenia brain is differentiated from the normal by subtle changes, with significant overlap in measures between and disease states. For past 25 years, has increasingly been considered a neurodevelopmental disorder. This frame of reference challenges biological researchers to consider how pathological changes identified adult tissue can be accounted for aberrant developmental processes occurring during fetal, childhood or adolescent periods. To place neuropathology context requires...

10.3389/fncel.2013.00060 article EN cc-by Frontiers in Cellular Neuroscience 2013-01-01

Cannabis contains over 70 unique compounds and its abuse is linked to an increased risk of developing schizophrenia. The behavioural profiles the psychotropic cannabis constituent Δ9-tetrahydrocannabinol (Δ9-THC) non-psychotomimetic cannabidiol (CBD) were investigated with a battery tests relevant anxiety positive, negative cognitive symptoms Male adult C57BL/6JArc mice given 21 daily intraperitoneal injections vehicle, Δ9-THC (0.3, 1, 3 or 10 mg/kg) CBD (1, 5, 50 mg/kg). produced classic...

10.1017/s1461145709990605 article EN The International Journal of Neuropsychopharmacology 2009-09-29

Endocannabinoids provide control over cortical neurotransmission. We investigated the developmental expression of key genes in endocannabinoid system across human postnatal life and determined whether they correspond to development markers for inhibitory interneurons, which shape development. used microarray with qPCR validation situ hybridisation quantify mRNA central receptor CB(1)R, synthetic enzymes (DAGLα 2-arachidonylglycerol [2-AG] NAPE-PLD anandamide), inactivating (MGL ABHD6 2-AG...

10.1186/1471-2202-13-87 article EN cc-by BMC Neuroscience 2012-07-24

The cannabis constituent cannabidiol (CBD) possesses anxiolytic and antipsychotic properties. We have previously shown that transmembrane domain neuregulin 1 mutant (Nrg1 TM HET) mice display altered neurobehavioural responses to the main psychoactive of cannabis, Δ9-tetrahydrocannabinol. Here we investigated whether Nrg1 HET respond differently CBD reverses schizophrenia-related phenotypes expressed by these mice. Adult male wild type-like littermates (WT) received vehicle or (1, 50 100...

10.1371/journal.pone.0034129 article EN cc-by PLoS ONE 2012-04-03

Abstract Heavy cannabis abuse increases the risk of developing schizophrenia. Adolescents appear particularly vulnerable to development psychosis-like symptoms after use. To test whether schizophrenia candidate gene neuregulin 1 (NRG1) modulates effects cannabinoids in adolescence, we tested male adolescent heterozygous transmembrane domain Nrg1 mutant (Nrg1 TM HET) mice and wild type-like littermates (WT) for their neurobehavioural response repeated Δ9-tetrahydrocannabinol (THC, 10 mg/kg...

10.1017/s1461145711001854 article EN The International Journal of Neuropsychopharmacology 2012-01-09

Delta(9)-tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis, accumulates in adipose tissue where it is stored for long periods time. Here we investigated whether conditions that promote lipolysis can liberate THC from adipocytes to yield increased blood levels THC.In vitro studies involved freshly isolated rat were incubated with before exposure lipolytic agent adrenocorticotrophic hormone (ACTH). A complementary vivo approach examined effects both food deprivation and...

10.1111/j.1476-5381.2009.00399.x article EN British Journal of Pharmacology 2009-08-14

Neuregulin 1 (NRG1) is linked to an increased risk of developing schizophrenia and cannabis dependence. Mice that are hypomorphic for Nrg1 (Nrg1 HET mice) display schizophrenia-relevant behavioural phenotypes aberrant expression serotonin glutamate receptors. mice also idiosyncratic responses the main psychoactive constituent cannabis, Δ9-tetrahydrocannabinol (THC). To gain traction on molecular pathways disrupted by hypomorphism Nrg1-cannabinoid interactions we conducted a proteomic study....

10.3389/fncel.2013.00015 article EN cc-by Frontiers in Cellular Neuroscience 2013-01-01

The effects of Δ9-tetrahydrocannabinol (Δ9-THC; 0.3, 1, 3 and 10 mg/kg), the fatty acid amide hydrolysis inhibitor URB-597 (0.1 0.3 on auditory olfactory go/no-go discrimination tasks were examined in rats. aims to assess (i) whether simple are sensitive cannabinoid interference (ii) manipulation endogenous levels with might have adverse perceptual cognitive functions. Thirsty rats trained nose poke at a ‘sniff port’, where odours briefly presented. After one odour (S+, lemon), licks made an...

10.1097/fbp.0b013e328345c82b article EN Behavioural Pharmacology 2011-04-21

Advanced glycation endproducts (AGE) have been implicated in the pathogenesis of diabetic complications, including cardiovascular dysfunctions. 3-benzyloxycarbonylmethyl-4-methyl-thiazol-3-ium bromide (C36), a novel AGE breaker, was investigated for its beneficial effects on system rats.The vitro breaking abilities C36 cross-links formed and vivo were assessed. After 4 weeks' treatment with C36, left ventricular functions (streptozotocin-induced) rats evaluated by haemodynamic studies....

10.1038/sj.bjp.0707533 article EN British Journal of Pharmacology 2007-10-29

Background The Neuregulin 1 transmembrane domain heterozygous mutant (Nrg1 TM HET) mouse is used to investigate the role of Nrg1 in brain function and schizophrenia-like behavioural phenotypes. However, molecular alterations expression that underpin observations have been assumed, but not directly determined. Here we comprehensively characterise mRNA transcripts throughout development HET mouse. In addition, regulation high-frequency (gamma) electrophysiological oscillations this associate...

10.1371/journal.pone.0124114 article EN cc-by PLoS ONE 2015-05-19

Surgeons use the Internet and social media to provide health information, promote their clinical practice, network with clinicians researchers, engage journal clubs online campaigns. While surgical patients are increasingly Internet-literate, prevalence purpose of searching for information vary among patient populations. We aimed characterise colorectal surgeon (CRS) seek information.Members Colorectal Society Australia New Zealand under care CRS at Royal Prince Alfred Hospital, Sydney, were...

10.1186/s12893-019-0518-4 article EN cc-by BMC Surgery 2019-05-24

Background: The Sydney Facial Nerve Service is a multidisciplinary team that provides management of patients with facial nerve disorders, historically as an in-person format. coronavirus disease 2019 (COVID-19) pandemic resulted in shift to virtual format due infection control precautions. This study aims evaluate the acceptability telehealth for and clinicians care palsy. Methods: questionnaires were distributed either on email or mail out. Follow up telephone calls made non-responders....

10.21037/ajo-24-5 article EN Australian Journal of Otolaryngology 2024-05-29

The major psychoactive constituent of the Cannabis sativa plant, Δ 9 -tetrahydrocannabinol (THC), has been extensively investigated for its therapeutic and toxicological effects. Cannabidiol, another abundant but nonpsychotropic recently attracted renewed interest as a molecule. Preliminary reports antipsychotic, antihyperalgesic, anticonvulsant, neuroprotective antiemetic properties, ability to counteract certain effects traditional cannabinoid receptor ligands, have augmented by discovery...

10.1358/dof.2005.030.07.915908 article EN Drugs of the Future 2005-01-01

Cannabis use is a well-established component risk factor for schizophrenia, particularly in adolescent individuals with genetic predisposition the disorder. Alterations to endocannabinoid system have been found prefrontal cortex of patients schizophrenia. Thus, we assessed whether molecular alterations exist signalling pathway during brain development mouse model schizophrenia gene neuregulin 1 (Nrg1). We analysed transcripts encoding key molecules heterozygous transmembrane domain Nrg1...

10.3389/fpsyt.2018.00011 article EN cc-by Frontiers in Psychiatry 2018-02-07

The aim of this report is to describe the management an iatrogenic diaphragmatic eventration following surgery relieve neurogenic symptoms thoracic outlet syndrome in a patient with prior history sleeve gastrectomy. We discuss case 46-year-old woman 6-month gastro-oesophageal reflux and dyspnoea. Imaging demonstrated left hemidiaphragm hiatus hernia. underwent laparoscopic plication hemidiaphragm, repair hernia, omega loop gastric bypass, satisfactory resolution her symptoms. This...

10.1093/jscr/rjae117 article EN cc-by-nc Journal of Surgical Case Reports 2024-02-21

Karl, Tim; Long, Leonora; Boucher, Aurelie; McGregor, Iain; Huang, Xu-Feng; Arnold, Jonathon Author Information

10.1097/01.fbp.0000434734.92528.09 article IT Behavioural Pharmacology 2013-10-01
Coming Soon ...